2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2151

Fractalkine (CX3CL1) Is Expressed By Arterial Endothelium and Vascular Smooth Muscle Cells (VSMC) in GCA
Abstract Number: 355

Fracture Incidence Rates in Solid Organ Transplant Recipients: A Systematic Review and Meta-Analysis
Abstract Number: 1023

Fracture Risk Reduction with Romosozumab: Results of a Phase 3 Study in Postmenopausal Women with Osteoporosis
Abstract Number: 1541

Frailty Is Associated with Decreased Physical Function in Adults with Rheumatoid Arthritis
Abstract Number: 2774

Framingham Risk Score Discriminates Coronary Atherosclerosis in Psoriatic Arthritis Patient Better Than Other Cardiovascular Scores Do
Abstract Number: 1513

FRAX Fracture Risk in Rheumatoid Arthritis – Assessments with and without Bone Mineral Density May Lead to Very Different Results in Individual Patients
Abstract Number: 1808

Frequency and Factors Associated with Thirty Day Hospital Readmissions Among Systemic Lupus Erythematosus Patients in a Community Hospital in the California Central Valley
Abstract Number: 1815

Frequency and Predictors of Attaining the Lupus Low Disease Activity State (LLDAS) in a Multinational SLE Cohort from the Asia Pacific
Abstract Number: 3021

Frequency of Arthralgia, Seropositivity, and Seropositive Arthralgia and Their Association with Development of Rheumatoid Arthritis in a Cohort of Indigenous North Americans with or without a First Degree Relative with Rheumatoid Arthritis
Abstract Number: 1385

Frequency of the Systemic Lupus Collaborating Clinics- Damage Index Items in Three Registries of Childhood-Onset Systemic Lupus Erythematosus
Abstract Number: 2162

Frequent Discussion of Insomnia and Weight Gain with Glucocorticoid Therapy: An Analysis of Twitter Posts
Abstract Number: 282

From ‘immune Mediated Necrotizing Myopathy’ to ‘antibody-Mediated Necrotizing Myositis: Towards the Pathogenic Role of Anti-SRP and Anti-Hmgcr Antibodies’
Abstract Number: 171

From 3D Printed Bones to Arthritis Patients – Arthro-Haptic Experience Supporting Disease Awareness
Abstract Number: 3064

From Art to Science: A Mobile App for Point-of-Care Relevance Determination for the Musculoskeletal Exam
Abstract Number: 2268

Fructose Amplifies Inflammatory Potential in Human Monocytic Cells Via Reduction of AMP-Activated Protein Kinase Activity

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].